RecruitingNCT07087327
Long-term EB-1020 safety in children and adolescents with ADHD
About this title
Read the official source — NCT07087327Medication studyAges 6–17Japan
Understand this study
Who could participate?
Listed age limits: 6 years to 17 years.
- Listed locations
- SapporoSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 16, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 180
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT07087327
- Official title
Show the full official title
A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Japan-China Joint Trial to Evaluate the Safety and Efficacy of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention- Deficit/Hyperactivity Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Sapporo
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including EB-1020 (Centanafadine) low dose and EB-1020 (Centanafadine) high dose.
Who can participate?
Listed age limits: 6 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
